NLRP3 Inflammasome Mediates Immune-Stromal Interactions in Vasculitis

Supplemental Digital Content is available in the text. Rationale: NLRP3 (NLR family pyrin domain containing 3) activation and IL-1β (interleukin-1β) production are implicated in Kawasaki disease (KD) pathogenesis; however, a detailed and complete characterization of the molecular networks and cellular subsets involved in the development of cardiovascular lesions is still lacking. Objective: Here, in a murine model of KD vasculitis, we used single-cell RNA sequencing and spatial transcriptomics to determine the cellular landscape of inflamed vascular tissues. Methods and Results: We observe infiltrations of innate and adaptive immune cells in murine KD cardiovascular lesions, associated with increased expression of Nlrp3 and Il1b. Monocytes, macrophages, and dendritic cells were the main sources of IL-1β, whereas fibroblasts and vascular smooth muscle cells (VSMCs) expressed high levels of IL-1 receptor. VSMCs type 1 surrounding the inflamed coronary artery undergo a phenotype switch to become VSMCs type 2, which are characterized by gene expression changes associated with decreased contraction and enhanced migration and proliferation. Genetic inhibition of IL-1β signaling on VSMCs efficiently attenuated the VSMCs type 2 phenotypic switch and the development of cardiovascular lesions during murine KD vasculitis. In addition, pharmacological inhibition of NLRP3 prevented the development of cardiovascular inflammation. Conclusions: Our studies unravel the cellular diversity involved in IL-1β production and signaling in murine KD cardiovascular lesions and provide the rationale for therapeutic strategies targeting NLRP3 to inhibit cardiovascular lesions associated with KD.

[1]  B. Cherqaoui,et al.  Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin–Resistant Kawasaki Disease , 2020, Arthritis & rheumatology.

[2]  M. Noval Rivas,et al.  Kawasaki disease: pathophysiology and insights from mouse models , 2020, Nature Reviews Rheumatology.

[3]  J. Coselli,et al.  Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice , 2020, Journal of the American Heart Association.

[4]  Y. Takeishi,et al.  Crucial role of NLRP3 inflammasome in a murine model of Kawasaki disease. , 2019, Journal of molecular and cellular cardiology.

[5]  J. Konvalinka,et al.  MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition , 2019, PLoS biology.

[6]  M. Fishbein,et al.  Intestinal Permeability and IgA Provoke Immune Vasculitis Linked to Cardiovascular Inflammation. , 2019, Immunity.

[7]  Lei Xu,et al.  The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. , 2019, International immunopharmacology.

[8]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[9]  Clint L. Miller,et al.  Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis , 2019, Nature Medicine.

[10]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[11]  E. Natour,et al.  Role of Vascular Smooth Muscle Cell Phenotypic Switching and Calcification in Aortic Aneurysm Formation. , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[12]  C. Day,et al.  MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition , 2019, Nature Chemical Biology.

[13]  Virginia Savova,et al.  Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. , 2019, Immunity.

[14]  Horacio Pérez-Sánchez,et al.  MCC950 closes the active conformation of NLRP3 to an inactive state , 2019, Nature Chemical Biology.

[15]  Xiaoqiong Gu,et al.  The IL-1B Gene Polymorphisms rs16944 and rs1143627 Contribute to an Increased Risk of Coronary Artery Lesions in Southern Chinese Children with Kawasaki Disease , 2019, Journal of immunology research.

[16]  Allon M Klein,et al.  Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data. , 2019, Cell systems.

[17]  M. Fishbein,et al.  Myocardial fibrosis after adrenergic stimulation as a long-term sequela in a mouse model of Kawasaki disease vasculitis. , 2019, JCI insight.

[18]  Lai Guan Ng,et al.  Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.

[19]  Atul J. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[20]  J. Kanegaye,et al.  Kawasaki Disease Outcomes and Response to Therapy in a Multiethnic Community: A 10‐Year Experience , 2018, The Journal of pediatrics.

[21]  C. Hoggart,et al.  Diagnosis of Kawasaki Disease Using a Minimal Whole-Blood Gene Expression Signature , 2018, JAMA pediatrics.

[22]  J. Stéphan,et al.  Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra. , 2018, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[23]  K. Schroder,et al.  MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice , 2018, Scientific Reports.

[24]  V. Pascual,et al.  Whole blood transcriptional profiles as a prognostic tool in complete and incomplete Kawasaki Disease , 2018, PloS one.

[25]  Charlotte Soneson,et al.  Bias, robustness and scalability in single-cell differential expression analysis , 2018, Nature Methods.

[26]  H. Reumaux,et al.  Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm , 2018, Cardiology in the Young.

[27]  G. Kaplanski.  Interleukin‐18: Biological properties and role in disease pathogenesis , 2017, Immunological reviews.

[28]  Kei Takahashi,et al.  Histopathological aspects of cardiovascular lesions in Kawasaki disease , 2017, International journal of rheumatic diseases.

[29]  Qingsong Liu,et al.  Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders , 2017, The Journal of experimental medicine.

[30]  C. Garlanda,et al.  IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity , 2017, Nature.

[31]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[32]  J. Kuiper,et al.  NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice—Brief Report , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[33]  B. McCrindle,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association , 2017, Circulation.

[34]  M. Fishbein,et al.  CD8+ T Cells Contribute to the Development of Coronary Arteritis in the Lactobacillus casei Cell Wall Extract–Induced Murine Model of Kawasaki Disease , 2017, Arthritis & rheumatology.

[35]  J. Burns,et al.  Review: Found in Translation: International Initiatives Pursuing Interleukin‐1 Blockade for Treatment of Acute Kawasaki Disease , 2017, Arthritis & rheumatology.

[36]  B. McCrindle,et al.  Inositol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease , 2016, The Journal of Immunology.

[37]  Patrik L. Ståhl,et al.  Visualization and analysis of gene expression in tissue sections by spatial transcriptomics , 2016, Science.

[38]  J. Newburger,et al.  Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). , 2016, Contemporary clinical trials.

[39]  M. Fishbein,et al.  Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease–Associated Abdominal Aortic Aneurysm , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[40]  V. Nizet,et al.  IL-1β is an innate immune sensor of microbial proteolysis. , 2016, Science immunology.

[41]  M. Fishbein,et al.  IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1&agr; and IL-1&bgr; , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[42]  J. Burns,et al.  The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease , 2015, Expert review of clinical immunology.

[43]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[44]  K. Schroder,et al.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases , 2015, Nature Medicine.

[45]  B. Moffett,et al.  Epidemiology of Immunoglobulin Resistant Kawasaki Disease: Results from a Large, National Database , 2015, Pediatric Cardiology.

[46]  C. Khor,et al.  Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease , 2014, Genome Medicine.

[47]  Wei-Chiao Chang,et al.  Single-Nucleotide Polymorphism rs7251246 in ITPKC Is Associated with Susceptibility and Coronary Artery Lesions in Kawasaki Disease , 2014, PloS one.

[48]  J. Orenstein,et al.  Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study , 2012, PloS one.

[49]  G. Owens,et al.  Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms. , 2012, Physiological genomics.

[50]  M. Fishbein,et al.  Interleukin-1&bgr; Is Crucial for the Induction of Coronary Artery Inflammation in a Mouse Model of Kawasaki Disease , 2012, Circulation.

[51]  G. Owens,et al.  Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. , 2012, The Journal of clinical investigation.

[52]  Calvin Lin,et al.  Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. , 2010, Human immunology.

[53]  C. Gabay,et al.  IL-1 pathways in inflammation and human diseases , 2010, Nature Reviews Rheumatology.

[54]  Kai-Sheng Hsieh,et al.  IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[55]  Yusuke Nakamura,et al.  ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms , 2008, Nature Genetics.

[56]  A. Daugherty,et al.  Interleukin-18 Enhances Atherosclerosis in Apolipoprotein E−/− Mice Through Release of Interferon-&ggr; , 2002, Circulation research.

[57]  S. Crawford,et al.  CTLA-4 (CD152) Expression in T Cells during the Acute Stage of Kawasaki Disease , 2003, Pediatric Research.

[58]  H. Jäck,et al.  IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. , 1997, Journal of Immunology.

[59]  J. Newburger,et al.  ENDOTHELIAL CELL ACTIVATION AND HIGH INTERLEUKIN-1 SECRETION IN THE PATHOGENESIS OF ACUTE KAWASAKI DISEASE , 1989, The Lancet.

[60]  P. Pelkonen,et al.  Circulating interleukin-1 beta in patients with Kawasaki disease. , 1988, The New England journal of medicine.

[61]  H. Kato,et al.  Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. , 1988, Clinical immunology and immunopathology.